NICE recommends Kymriah® for routine NHS use, offering immense benefits for those with resistant B-...
Read moreWe explore CAR T-cell therapy challenges, regulatory approvals, market growth, pricing models, and a...
Read moreSafety signals have sparked vital discussions on patient access to ATMPs, marking a pivotal moment i...
Read moreObjectives The objective of this study is to explore the role of economic benefit in the HTA decisio...
Read moreBack in January this year, we summarised the key trends our market access experts believed would dom...
Read moreThe MHRA grants conditional approval to Casgevy, the first-ever CRISPR gene-editing therapy for sick...
Read moreWe summarise the World Orphan Drug Congress Europe 2023 including keynote and panel sessions on EU H...
Read moreWe've updated our 2019 analysis which compares the annual and lifetime treatment costs of the 10 mos...
Read moreWe outline the challenges pharma companies encounter when launching cell and gene therapies, and ass...
Read moreWe summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...
Read more